Page 89 - Strategies for non-invasive managementof high-grade cervical intraepithelial neoplasia - prognostic biomarkers and immunotherapy Margot Maria Koeneman

Study results
The main study results are summarized in table 2. A total of 407 patients were included, of which 385 patients were diagnosed with ASCUS/LSIL/low-grade CIN and 22 patients were diagnosed with HSIL or high-grade CIN. Only five patients had a histological diagnosis of high-grade CIN. Pooling of the study results was not possible, due to a marked heterogeneity in patient populations, follow-up terms and outcome-measures. Only five out of 155 patients (3.2%) without 3q26 gain showed disease persistence or progression.
3q26 as a prognostic biomarker
Table 2. Results of studies on 3q26/hTERC gain as a prognostic biomarker in CIN
4
Author
Gain of 3q26/hTERC per outcome group (using study threshold)
Progression in gain-negative group
Test properties
Prediction of persistence/ progression vs regression
Prediction of progression vs regression/ persistence
Heselmayer- Only 3q26 gain: 5/15 Haddad, Progression: 7/12
2005 Regression: 0/10
3q26 gain and/or
tetraploidy: 0/7 Progression: 12/12
Regression: 3/10
Alameda, 6 months NR 2009 Regression: 7/15
Sensa 100%
Specb 70%
PPVc 80%
NPVd 100%
(progression vs regression, gain+ tetraploidy group)
6 months Sens 80% Spec 53%
Persistence/ progression:
12/15 PPV 63%
12/24 months
Regression: 8/18
Persistence/ progression:
6/8 PPV 43%
NPV 73% 12/24 months Sens 75% Spec 53%
Jalali, 2010 Regression/ persistence: 1/30 7/36
Progression: 10/11
Lan, 2012 Regression: 2/20 0/27 Persistence: 12/21
Progression: 13/13
Rodolakis, Regression/ persistence: 0/32 2012 5/37
Progression: 3/3
NPV 91%
Sens 74% Spec 90% PVV 93% NPV 67%
Sens 91% Spec 81% PPV 59% NPV 97%
Sens 100% Spec 66% PPV 48% NPV 100%
Sens 100% Spec 89% PPV 50% NPV 100%
table continues
87